Chelsie Derman

At NASPGHAN 2024, HCPLive spoke with Duncan about how treating infants who appear to have reflux may actually result in greater repeat hospital visits.

GERD diagnoses in BRUE infants were linked to frequent acid suppression use and repeat hospital visits, according to a study presented at NASPGHAN 2024.

HCPLive spoke with Lat at NASPGHAN 2024 about how for communities with high H. pylori prevalence, it is best to test for H. pylori before a colonoscopy.

At NASPGHAN 2024, Okuno shared findings on reduced parental stress after children’s tube weaning, emphasizing the potential for new outpatient weaning protocols.

HCPLive spoke with Okuno at NASPGHAN 2024 about a study examining changes in parent stress levels and mental health symptoms after a child completes weaning off tube feeding.

At NASPGHAN, HCPLive spoke with Margolis about her team’s study on the link between maternal SSRI exposure and an infant’s development of gut-brain interaction disorders.

A study found a 3.5-fold increased schizophrenia risk in those with hallucinogen-related emergency department visits.

A study presented at NASPGHAN 2024 reveals rising incidence rates and improved survival outcomes of Biliary Atresia in the US.

Maternal SSRI use was linked to a higher risk of constipation in infants, while untreated maternal depression was tied to colic. Margolis discussed these findings at NASPGHAN.

Silberg urges wider physician education on celiac screening, stressing that guidelines must reach primary care to address disparities and misconceptions.

A study presented at NASPGHAN 2024 found only 10% of eligible kids were screened for celiac disease. Debra Silberg, MD, PhD, urges unbiased, consistent screening.

Emraclidine fails to significantly reduce schizophrenia symptoms in phase 2 EMPOWER trials, with no statistical difference from placebo on PANSS score.

At NASPGHAN 2024, Collen told HCPLive the promising early data of advanced combination therapy for pediatric refractory IBD although hurdles exist.

HCPLive spoke to Collen at NASPGHAN 2024 about early research on environmental exposures prevalent in children with Crohn’s Disease.

At NASPGHAN 2024, Sadaka shared results of a study demonstrating the factors associated with a longer hospital stay for children with gastroparesis.

HCPLive spoke to Sadaka at NASPHAN 2024 about the increase in hospital admissions among children with gastroparesis after the COVID-19 pandemic.

At NASPGHAN 2024, HCPLive spoke to Shameem about his study on inpatient outcomes of pediatric patients with IBD and GAD vs patients without GAD.

Although children on baclofen had numerically greater improvements in rumination syndrome symptoms than those on placebo, the group difference was insignificant.

Phase 3 data shows lumateperone 42 mg significantly delayed relapse in patients with schizophrenia vs placebo, with 63% reduced relapse risk and good tolerance.

Teva presents 2 findings at the 2024 psychiatry conference: TEV’749’s effects on social function and quality of life in adults with schizophrenia and risperidone adherence patterns.

Chronic hepatitis B patients with HBsAg <100 IU/mL and HBcrAg <3 log U/mL at nucleot(s)ide analog therapy had lower relapse risk.

Normothermic machine perfusion in liver transplants improves preservation, reduces early complications, and shows promise in complex cases.

Clinical images help pathologists improve diagnostic confidence and agreement, leading to more accurate diagnoses of melanocytic skin lesions.

More patients with atopic dermatitis on stapokibart than on placebo achieved ≥ 75% improvement in Eczema Area and Severity Index over 52 weeks.

Neither clinician peer comparison nor patient informational mail reduced benzodiazepine use among older adults in anesthesia care, a new study finds.

In a recent phase 2a trial, SPN-820, a novel intracellular moderator of mTORC1, decreased suicidal ideation by 80%.

This Month in Review captures top FDA news, phase 2b data, and early research in the psychiatry field.

EMERGENT-4 and EMERGENT-5, phase 3, 52-week trials, showed xanomeline trospium chloride significantly improved schizophrenia symptoms across 52 weeks.

T-VASI and F-VASI are validated, responsive tools for assessing vitiligo severity and re-pigmentation, with meaningful change thresholds established.

Sexual trauma and genetic risk independently and together raise mental illness risk, a new study found.